medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2024, Número 1

<< Anterior Siguiente >>

Dermatología Cosmética, Médica y Quirúrgica 2024; 22 (1)


Guía rápida para el manejo de cicatrices queloides

Angulo RA, Alcalá PD

Idioma: Español
Referencias bibliográficas: 36
Paginas: 39-45
Archivo PDF: 247.88 Kb.


RESUMEN

Las cicatrices queloides son alteraciones fibroproliferativas derivadas de un cambio en el proceso de cicatrización. Actualmente no existen guías internacionales para su manejo, por lo que en ocasiones son un reto terapéutico. Realizamos una revisión de la literatura sobre las terapias no invasivas, inyectables y quirúrgicas disponibles, con el objetivo de proponer una guía rápida de tratamiento. Presentamos un flujograma que muestra la evaluación y manejo que ha dado resultados favorables para los autores.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Wu W, Zhao Y, Chen Y et al., Comparing the efficacy of multipledrugs injection for the treatment of hypertrophic scars andkeloid: a network meta-analysis, Aesthetic Plast Surg 2023;47(1):465-472. doi: 10.1007/s00266-022-03163-4.

  2. Thornton NJ, García BA, Hoyer P et al., Keloid scars: an updatedreview of combination therapies, Cureus 2021; 13(1):e12999.doi: 10.7759/cureus.12999.

  3. Liu R, Xiao H, Wang R et al., Risk factors associated with the progressionfrom keloids to severe keloids, Chin Med J (Inglaterra)2022; 5:135(7):828-36. doi: 10.1097/CM9.0000000000002093.

  4. Limandjaja GC, Niessen FB, Scheper RJ et al., The keloiddisorder: heterogeneity, histopathology, mechanisms andmodels, Front Cell Dev Biol 2020; 26:8:360. doi: 10.3389/fcell.2020.00360.

  5. Sadiq A, Khumalo NP y Bayat A, Genetics of keloid scarring.Textbook on scar management: state of the art managementand emerging technologies, Cham, Springer, 2020, 8. pmid:36351116.

  6. Brown JJ, Ollier WE, Thomson W et al., Positive association ofhla-drb1*15 with keloid disease in Caucasians, Int J Immunogenet2008; 35(4-5):303-7. doi: 10.1111/j.1744-313X.2008.00780.x.

  7. Ogawa R, Okai K, Tokumura F et al., The relationship betweenskin stretching/contraction and pathologic scarring:the important role of mechanical forces in keloid generation,Wound Repair Regen 2012; 20(2):149-57. doi: 10.1111/j.1524-475X.2012.00766.x.

  8. Ogawa R y Akaishi S, Endothelial dysfunction may play a keyrole in keloid and hypertrophic scar pathogenesis: keloids andhypertrophic scars may be vascular disorders, Med Hypotheses2016; 96:51-60. doi: 10.1016/j.mehy.2016.09.024.

  9. Berman B, Maderal A y Raphael B, Keloids and hypertrophicscars: pathophysiology, classification, and treatment,Dermatol Surg 2017; 43 Suppl 1:S3-18. doi: 10.1097/DSS.0000000000000819.

  10. Rousselle P, Montmasson M y Garnier C, Extracellular matrixcontribution to skin wound re-epithelialization, Matrix Biol 2019;75-76:12-26. doi: 10.1016/j.matbio.2018.01.002.

  11. Butzelaar L, Niessen FB, Talhout W et al., Different properties ofskin of different body sites: the root of keloid formation?, WoundRepair Regen 2017; 25(5):758-66. doi: 10.1111/wrr.12574.

  12. Yin Q, Niessen FB, Gibbs S et al., Intralesional corticosteroid administrationin the treatment of keloids: a survey among Dutchdermatologists and plastic surgeons, J Dermatolog Treat 2023;34(1):2159308. doi: 10.1080/09546634.2022.2159308.

  13. Limandjaja GC, Niessen FB, Scheper RJ et al., Hypertrophicscars and keloids: overview of the evidence and practical guidefor differentiating between these abnormal scars, Exp Dermatol2021; 30(1):146-61. doi: 10.1111/exd.14121.

  14. Ud-Din S. y Bayat A, Strategic management of keloid disease inethnic skin: a structured approach supported by the emergingliterature, The British Journal of Dermatology 2013; 169(3):71.81.Disponible en: https://doi.org/10.1111/bjd.12588.

  15. Bran GM, Goessler UR, Hormann K et al., Keloids: current conceptsof pathogenesis (review), Int J Mol Med 2009; 24(3):283-93. doi: 10.3892/ijmm_00000231.

  16. Ogawa R, Keloid and hypertrophic scars are the result ofchronic inflammation in the reticular dermis, Int J Mol Sci 2017;18(3):606. doi: 10.3390/ijms18030606.

  17. Ogawa R, Akaishi S y Hyakusoku H, Differential and exclusivediagnosis of diseases that resemble keloids and hypertrophicscars, Ann Plast Surg 2009; 62(6):660-4. doi: 10.1097/SAP.0b013e31817e9d67.

  18. Ogawa R, Keloids and hypertrophic scars, UpToDate 2022: 1-35.Disponible en: https://www.uptodate.com/contents/keloidsand-hypertrophic-scars.

  19. Kim SW, Management of keloid scars: noninvasive and invasivetreatments, Arch Plast Surg 2021; 48(2):149-57. doi: 10.5999/aps.2020.01914.

  20. Puri N y Talwar A, The efficacy of silicone gel for the treatmentof hypertrophic scars and keloids, J Cutan Aesthet Surg 2009;2(2):104-6. doi: 10.4103/0974-2077.58527.

  21. Heppt MV, Breuninger H, Reinholz M et al., Current strategiesin the treatment of scars and keloids, Facial Plastic Surgery2015; 31(4):386-95. doi:10.1055/s-0035-1563694.

  22. Barone N, Safran T, Vorstenbosch J et al., Current advances inhypertrophic scar and keloid management, Semin Plast Surg2021; 35(3):145-52. doi: 10.1055/s-0041-1731461.

  23. Ekstein SF, Wyles SP, Moran SL et al., Keloids: a review of therapeuticmanagement, Int J Dermatol 2021; 60(6):661-71. doi:10.1111/ijd.15159.

  24. Khalid FA, Mehrose MY, Saleem M et al., Reply to commentson “comparison of efficacy and safety of intralesional triamcinoloneand combination of triamcinolone with 5-fluorouracil in thetreatment of keloids and hypertrophic scars: randomised controltrial”, Burns 2020; 46(2):491-2. doi: 10.1016/j.burns.2018.12.014.

  25. Moravej H, Forghanian A, Dadkhahfar S et al., Intralesional bleomycinversus intralesional triamcinolone in the treatment of keloidsand hypertrophic scars, Dermatol Ther 2022; 35(9):e15730.doi: 10.1111/dth.15730.

  26. Gauglitz GG, Korting HC, Pavicic T et al., Hypertrophic scarringand keloids: pathomechanisms and current and emerging treatmentstrategies, Mol Med 2011; 17(1-2):113-25. doi: 10.2119/molmed.2009.00153.

  27. Thornton NJ, García BA, Hoyer P et al., Keloid scars: an updatedreview of combination therapies, Cureus 2015; 13(1):e12999.doi: 10.7759/cureus.12999.

  28. Chan LJ y Greenberg HL, Establishment of an efficacioustreatment period for prophylaxis of auricular keloid recurrencepostexcision using topical imiquimod 5%: a demonstrativecase series, jaad Case Rep 2022; 30(26):41-4. doi: 10.1016/j.jdcr.2022.06.012.

  29. Betarbet U y Blalock TW, Keloids: a review of etiology, prevention,and treatment, J Clin Aesthet Dermatol 2020; 13(2):33-43.

  30. Mari W, Alsabri SG, Tabal N et al., Novel insights on understandingof keloid scar: article review, J Am Coll Clin Wound Spec2016; 7(1-3):1-7. doi: 10.1016/j.jccw.2016.10.001.

  31. Arno AI, Gauglitz GG, Barret JP et al., Up-to-date approach tomanage keloids and hypertrophic scars: a useful guide, Burns2014; 40(7):1255-66. doi: 10.1016/j.burns.2014.02.011.

  32. Litrowski N, Boullie MC, Dehesdin D et al., Treatment of earlobekeloids by surgical excision and cryosurgery, J Eur Acad DermatolVenereol 2014; 28(10):1324-31. doi: 10.1111/jdv.12282. Epub2013 Oct 3. PMID: 24118593.

  33. Chen F, Kuo YR, Huang CJ et al., Lesion site is the key prognosticfactor for keloid patients receiving surgery with adjuvantradiotherapy, Ann Plast Surg 2022; 89(6):626-30. doi: 10.1097/SAP.0000000000003315.

  34. Garg GA, Sao PP y Khopkar US, Effect of carbon dioxide laserablation followed by intralesional steroids on keloids, J CutanAesthet Surg 2011; 4(1):2-6. doi: 10.4103/0974-2077.79176.

  35. Limmer EE y Glass DA Jr, A review of current keloid management:mainstay monotherapies and emerging approaches,Dermatol Ther (Heidelberg) 2020; 10(5):931-48. doi: 10.1007/s13555-020-00427-2.

  36. Jacobs C y Wilmink J, Combined versus single treatment regimensfor keloid therapy using serial intralesional corticosteroidinjections, surgical excision, silicone and/or cryotherapy, jprasOpen 2021; 29:157-66. doi: 10.1016/j.jpra.2021.05.011.




2020     |     www.medigraphic.com